The hypothesis was tested that an acute oxidation deficiency related to potential dietary trigger factors plays a role in the migraine attack. Migraine sufferers (14F and 4M), fulfilling the criteria for migraine with and without aura according to the classification of the International Headache Society, were coadministered oral mephenytoin (100 mg) and debrisoquine (10 mg) during the initial phase of a typical migraine attack. This was repeated during a period without migraine. The hydroxylation of mephenytoin and debrisoquine hydroxylation did not differ during and without the migraine attack. We conclude that hydroxylation, via cytochrome P-450 (2D6, 2C8 and 9), is not reduced during the migraine attack. The results do not support the hypothesis that oxidation deficiency is involved in the pathophysiology of migraine.
GloverVLittlewoodJSandlerMPeatfieldRPettyRRoseFCDietary migraine: looking beyond tyramine. In:RoseFC ed.Progress in migraine research 2.London:Pitman1984:11319
2.
DaltonKFood intake prior to a migraine attack; study of 2313 spontaneous attacks.Headache1975;15:188–93
3.
AmeryWKDaviesPTCaersLIHepatic cytochrome P-450-mediated oxidation function in migraine.Cephalalgia1988;8:71–4
4.
Headache Classification Committee of the International Headache Society,Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.Cephalalgia1988;8:196
5.
SanzEJVillénTAlmCBertilssonLS-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine.Clin Pharmacol Ther1989;45:495–9
6.
LennardMSSilasJHSmithAJTuckerGTDetermination of debrisoquine and its 4-hydroxymetabolite in biologic fluids by gas chromatography with flame ionization and nitrogen-selective detection.J Chromatogr1977;133:161–6
7.
WedlundPJAslanianWSMcAllisterCBWilkinsonGRBranchRAMephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.Clin Pharmacol Ther1984;36:773–80
8.
KüpferAPreisigRPharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.Eur J Clin Pharmacol1984;26:753–9
9.
SteinerEBertilssonLSäweJBertlingISjöqvistFPolymorphic debrisoquine hydroxylation in 757 Swedish subjects.Clin Pharmacol Ther1988;44:431–5
10.
InabaTJurimaMNakanoMKalowWMephenytoin and sparteine pharmacogenetics in Canadian Caucasians.Clin Pharmacol Ther1984;36:670–66
11.
InabaTJurimaMMahonWAKalowWIn vitro inhibition studies of two isozymes of human liver cytochrome P-450.Drug Metab Dispos1985;13:443–8
12.
NakamuraKGotoFRayWAInterethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanse and Caucasian populations.Clin Pharmacol Ther1985;38:402–8
13.
PearlGFBoutagyJShenfieldGMDebrisoquine oxidation in an Australian population.Br J Clin Pharmacol1986;21:465–71
14.
SilasJHLennardMSTuckerGTRamsayLEWoodsHFPolymorphic metabolism of ß-adrenoceptor antagonists.Br J Clin Pharmacol1984;17:11S–19S
15.
MellströmBBertilssonLSäweJSchulzH-USjöqvistFE-and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.Clin Pharmacol Ther1981;30:189–93
16.
MellströmBSäweJBertilssonLSjöqvistFAmitriptyline metabolism: association with debrisoquine hydroxylation in non-smokers.Clin Pharmacol Ther1986;39:369–71
17.
BrøsenKKlysnerRGramLFOttonSVBechPBertilssonLSteady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.Eur J Clin Pharmacol1986;30:679–84
18.
SpinaEBirgerssonCyon BahrCPhenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.Clin Pharmacol Ther1984;36:677–82
19.
BertilssonLHenthornTKSanzETybringGSäweJVillénTImportance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype.Clin Pharmacol Ther1989;45:348–55
20.
AnderssonTC-GRegårdhM-JDahl-PuustinenBertilssonLSlow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.Therapeutic Drug Monitoring1990;12:415–16
